Pierre-dominique D. Ghislain
Brussels, BRU, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.
Journal: The Lancet regional health. Europe
Published: January 29, 2026
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.
Journal: Psoriasis (Auckland, N.Z.)
Published: January 05, 2026
Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA.
Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA.
Journal: Dermatology and therapy
Published: December 18, 2025
Real-World Effectiveness of Brodalumab in Challenging Psoriasis Subgroups: Insights from the PSO-TARGET Cohort.
Journal: Dermatology and therapy
Published: October 16, 2025
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.
Journal: Psoriasis (Auckland, N.Z.)
Published: March 06, 2025
PSO-TARGET: a New Tool to Identify the Therapeutic Expectations of Psoriasis Patients Treated with Biologics.
Journal: Dermatology and therapy
Published: December 31, 2024
Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
Journal: European journal of dermatology : EJD
Published: March 11, 2024
Belgian recommendations for managing psoriasis in a changing treatment landscape.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 06, 2024
Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real-life multicentric observational study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 31, 2023
Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
Journal: Dermatology and therapy
Published: August 03, 2023
Correction to: Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
Journal: Advances in therapy
Published: May 28, 2023
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Journal: American journal of clinical dermatology
Published: April 03, 2023
Last Updated: 09/26/2026